<DOC>
	<DOCNO>NCT01228760</DOCNO>
	<brief_summary>The purpose dose escalation study determine Maximum Tolerated Dose ( MTD ) recommend Phase 2 dose ASG-5ME subject castration-resistant prostate cancer ( CRPC ) .</brief_summary>
	<brief_title>A Study Determine Maximum Tolerated Dose ASG-5ME Subjects With Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description>The study two component . The first aim establish safe dose ASG-5ME . Once identify , safety preliminary estimate antitumor activity ASG-5ME test additional subject castration-resistant prostate cancer ( CRPC ) either chemotherapy naïve chemotherapy expose expanded cohort .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Subject histologicallyconfirmed castrationresistant prostate cancer meet least 1 follow criterion : subject 's disease progress available standard therapy OR effective standard therapy available treat subject 's disease OR subject disease suitable standard therapy OR subject chooses defer decline standard therapy ( subject adequately informed availability clinically meaningful therapy chooses instead partake research use product document clinical activity ) Testosterone ≤ 50 ng/dL Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy &gt; 6 month evaluate documented investigator Hematologic function , follow ( red blood cell ( RBC ) platelet transfusion allow within 4 week first dose ASG5ME ) : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L Hemoglobin ≥ 9 g/dL Renal function , follow : creatinine ≤ 1.5 x upper limit normal ( ULN ) , creatinine clearance &gt; 60 mL/min serum creatinine &gt; 2.0 mg/dL Total bilirubin &lt; 1 . 5 x ULN Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) ≤ 1.5 x ULN International Normalized Ratio ( INR ) &lt; 1.3 ( &lt; 3.0 therapeutic anticoagulation ) Serum calcium ≤ ULN Subjects must take agree remain stable dose luteinizing hormonereleasing hormone ( LHRH ) agonist therapy gonadotropinreleasing hormone ( GnRH ) antagonist duration trial surgically castrate Additional Inclusion criterion Chemotherapy Naïve Cohort : No prior systemic cytotoxic chemotherapy Additional Inclusion criterion Chemotherapy Exposed Cohort : Documented disease progression docetaxel treatment intolerability docetaxel treatment No additional prior chemotherapy CRPC allow History central nervous system metastasis , include incompletely treat epidural disease History primary malignancy ( include premalignant myeloid malignancy e.g . myelodysplastic syndrome ) , unless : Curatively resect nonmelanomatous skin cancer Other malignancy curatively treat know active disease present treatment administer last 3 year Active angina Class III IV Congestive Heart Failure ( CHF ) ( New York Heart Association CHF Functional Classification System ) clinically significant cardiac disease within 12 month study enrollment , include myocardial infarction , unstable angina , grade 2 great peripheral vascular disease , congestive heart failure , uncontrolled hypertension , arrhythmias control outsubject medication The following treatment allow within 4 week enrollment : cytotoxic chemotherapy , radiation therapy dietary supplement PCSPES Use prednisone ( equivalent corticosteroid ) &gt; 20 mg/day allow . Doses &lt; 20 mg/day allow dose &gt; 4 week Use antiandrogen therapy ( ie , flutamide , bicalutamide nilutamide ) within 6 week study enrollment ; nonresponders secondline antiandrogen therapy require 6 week withdrawal period Monoclonal antibody therapy within 3 month enrollment exception denosumab ( prior concurrent use denosumab allow ) Peripheral neuropathy ≥ grade 2 define CTCAE criterion version 4.0 Major surgery ( require general anesthesia ) within 4 week study enrollment Active infection require treatment systemic ( intravenous oral ) antiinfectives ( antibiotic , antifungal , antiviral agent ) within 72 hour screen Use investigational drug ( include market drug approve indication ) within 30 day prior enrollment History thromboembolic event bleed disorder ≤ 3 month ( e.g. , deep vein thrombosis ( DVT ) pulmonary embolism ( PE ) ) Known positive test human immunodeficiency virus ( HIV ) , hepatitis C , hepatitis B surface antigen</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Castration-Resistant Prostate Cancer</keyword>
	<keyword>ASG-5ME</keyword>
	<keyword>Pharmacokinetics ASG-5ME</keyword>
</DOC>